AIM Vaccine Co., Ltd. 06660.HK의 지난 분기 매출 실적은 어땠나요?
AIM Vaccine Co., Ltd.의 매출 추정치는 얼마인가요?
AIM Vaccine Co., Ltd.의 수익 품질 점수는 얼마인가요?
AIM Vaccine Co., Ltd.는 언제 수익을 보고하나요?
AIM Vaccine Co., Ltd.의 예상 수익은 얼마인가요?
AIM Vaccine Co., Ltd.은 수익 기대치를 충족했나요?
주요 통계
이전 종가
--
시가
--
일일 범위
-
52주 범위
-
거래량
--
평균 거래량
626.4K
EPS(TTM)
-0.25
배당수익률
--
시가총액
--
AIM VACCINE란 무엇인가요?
AIM Vaccine Co., Ltd. engages in biological vaccine technology development, technology transfer, and technical services. The company is headquartered in Beijing, Beijing and currently employs 1,493 full-time employees. The company went IPO on 2022-10-06. The firm's commercialized products mainly include recombinant HBV vaccine, freeze dried human rabies vaccine, inactivated HAV vaccine, mumps vaccine, bivalent inactivated HFRS vaccine and Group A, C, Y and W135 MPSV. The firm's vaccine products under development include 13-Valent Pneumonia Conjugate Vaccine, 24-Valent Pneumonia Conjugate Vaccine, quadrivalent influenza virus vaccine, iterative serum-free rabies vaccine, mRNA shingles/herpes zoster vaccine, Iterative mRNA rabies vaccine, mRNA respiratory syncytial virus vaccine, novel-process highly-effective human diploid rabies vaccine, and others.